ADMA Biologics (NASDAQ:ADMA) Trading Up 8.2%

ADMA Biologics, Inc. (NASDAQ:ADMAGet Rating)’s share price was up 8.2% during mid-day trading on Friday . The stock traded as high as $3.57 and last traded at $3.55. Approximately 83,124 shares were traded during trading, a decline of 97% from the average daily volume of 2,680,269 shares. The stock had previously closed at $3.28.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on ADMA shares. HC Wainwright lifted their target price on shares of ADMA Biologics from $4.00 to $4.50 and gave the company a “buy” rating in a research report on Tuesday, January 3rd. Mizuho lifted their target price on shares of ADMA Biologics from $5.00 to $6.00 and gave the company a “buy” rating in a research report on Thursday, November 10th. Finally, StockNews.com began coverage on shares of ADMA Biologics in a report on Wednesday, October 12th. They issued a “sell” rating for the company.

ADMA Biologics Stock Up 6.7 %

The stock’s fifty day moving average is $3.47 and its 200 day moving average is $2.84. The company has a current ratio of 5.04, a quick ratio of 1.38 and a debt-to-equity ratio of 1.51. The company has a market capitalization of $688.72 million, a P/E ratio of -9.46 and a beta of 0.92.

ADMA Biologics (NASDAQ:ADMAGet Rating) last posted its quarterly earnings results on Wednesday, November 9th. The biotechnology company reported ($0.08) EPS for the quarter, meeting analysts’ consensus estimates of ($0.08). ADMA Biologics had a negative net margin of 53.89% and a negative return on equity of 52.73%. The company had revenue of $41.09 million during the quarter, compared to analyst estimates of $34.57 million. Research analysts predict that ADMA Biologics, Inc. will post -0.3 EPS for the current fiscal year.

Insider Buying and Selling at ADMA Biologics

In related news, CEO Adam S. Grossman acquired 14,983 shares of ADMA Biologics stock in a transaction on Friday, December 9th. The shares were acquired at an average cost of $2.86 per share, with a total value of $42,851.38. Following the transaction, the chief executive officer now owns 2,203,708 shares in the company, valued at $6,302,604.88. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 5.90% of the company’s stock.

Institutional Trading of ADMA Biologics

Hedge funds and other institutional investors have recently modified their holdings of the business. Mackenzie Financial Corp purchased a new stake in ADMA Biologics during the 2nd quarter valued at about $258,000. Viewpoint Capital Management LLC purchased a new stake in ADMA Biologics during the 2nd quarter valued at about $26,000. Virtu Financial LLC purchased a new stake in ADMA Biologics during the 2nd quarter valued at about $34,000. Price T Rowe Associates Inc. MD bought a new position in ADMA Biologics during the 2nd quarter valued at about $35,000. Finally, Wealthstream Advisors Inc. bought a new position in ADMA Biologics during the 2nd quarter valued at about $36,000. 71.17% of the stock is owned by hedge funds and other institutional investors.

ADMA Biologics Company Profile

(Get Rating)

ADMA Biologics, Inc operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations.

Featured Articles

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.